LOS ANGELES--(BUSINESS WIRE)--Response Genetics, Inc. (Nasdaq:RGDX) will announce the results of studies that support the validity of using the molecular markers, excision repair cross-complementing factor 1 (ERCC1) and thymidylate synthase (TS) to help guide the selection of chemotherapy treatment for patients with colon cancer, non-small cell lung cancer (NSCLC) and ovarian cancer. Results of these studies are to be presented during the 2008 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, which will be held May 30 to June 3.
